Antifungal Therapy and Probiotics in Women's Health - A Comprehensive Review
Abstract
Candida-induced infections affect millions of women around the world. Therefore, the purpose of this review is to provide a comprehensive analysis of the role of antifungal therapy and probiotics in managing one such infection, vulvovaginal candidiasis (VVC). The study employed a systematic review method to retrieve relevant articles from databases such as PubMed, MDPI, Scopus, and ResearchGate, using specific search criteria. The findings highlight the effectiveness and limitations of traditional antifungal treatment, the emergence of novel treatments targeting new biological pathways, and the potential of probiotics as adjunctive therapy. It is concluded that while traditional antifungals remain fundamental, resistance issues necessitate ongoing development of novel agents. Additionally, alternative therapies hold promise in enhancing treatment outcomes and maintaining vaginal health. The multifaceted approach in VVC treatment highlights the importance of integrating various infection control and treatment strategies into a more effective and holistic approach.
Keywords: Candida sp.; Vulvovaginal candidiasis; Antifungal agents; Probiotics
Full Text:
PDFReferences
Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Critical Reviews in Microbiology, (2016); 42(6): 905-927.
Willems HME, Ahmed SS, Liu J, Xu Z, Peters BM. Vulvovaginal Candidiasis: A Current Understanding and Burning Questions. Journal of Fungi, (2020); 6(1): 27.
San Juan Galán J, Poliquin V, Gerstein AC. Insights and advances in recurrent vulvovaginal candidiasis. PLOS Pathogens, (2023); 19(11): e1011684.
Denning DW. Global incidence and mortality of severe fungal disease. The Lancet Infectious Diseases, (2024); 24(7): e428-e438.
Bitew A, Abebaw Y. Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. BMC Womens Health, (2018); 18(1): 94.
Logan A, Wolfe A, Williamson JC. Antifungal Resistance and the Role of New Therapeutic Agents. Current Infectious Disease Reports, (2022); 24(9): 105-116.
Murphy SE, Bicanic T. Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis. Frontiers in Cellular and Infection Microbiology, (2021); 11: 759408.
Bouz G, Doležal M. Advances in Antifungal Drug Development: An Up-To-Date Mini Review. Pharmaceuticals, (2021); 14(12): 1312.
Perlin DS. Cell Wall-Modifying Antifungal Drugs. In: Latgé JP, ed. The Fungal Cell Wall: An Armour and a Weapon for Human Fungal Pathogens. Current Topics in Microbiology and Immunology. 2020; 255-275. Springer International Publishing.
Jospe-Kaufman M, Ben-Zeev E, Mottola A, Dukhovny A, Berman J, Carmeli S et al. Reshaping Echinocandin Antifungal Drugs To Circumvent Glucan Synthase Point-Mutation-Mediated Resistance. Angewandte Chemie, (2024); 136(9): e202314728.
Silva-Dias A, Miranda IM, Branco J, Monteiro-Soares M, Pina-Vaz C, Rodrigues AG. Adhesion, biofilm formation, cell surface hydrophobicity, and antifungal planktonic susceptibility: relationship among Candida spp. Frontiers in Microbiology, (2015); 6: 205.
Rauseo AM, Coler-Reilly A, Larson L, Spec A. Hope on the horizon: novel fungal treatments in development. Open Forum Infectious Diseases, (2020); 7(2): ofaa016.
Wiederhold NP. Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents. Journal of Fungi, (2022); 8(8): 857.
Bibi M, Murphy S, Benhamou RI, Rosenberg A, Ulman A, Bicanic T et al. Combining Colistin and Fluconazole Synergistically Increases Fungal Membrane Permeability and Antifungal Cidality. ACS Infectious Diseases, (2021); 7(2): 377-389.
Scorzoni L, Fuchs BB, Junqueira JC, Mylonakis E. Current and promising pharmacotherapeutic options for candidiasis. Expert Opinion on Pharmacotherapy, (2021); 22(7): 887-888.
Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R et al. The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs, (2021); 81(15): 1703-1729.
McCarty TP, Pappas PG. Antifungal Pipeline. Frontiers in Cellular and Infectious Microbiology, (2021); 11: 732223.
Shao Y, Molestak E, Su W, Stankevič M, Tchórzewski M. Sordarin— An anti-fungal antibiotic with a unique modus operandi. British Journal of Pharmacology, (2022); 179(6): 1125-1145.
Ajetunmobi OH, Badali H, Romo JA, Ramage G, Lopez-Ribot JL. Antifungal therapy of Candida biofilms: Past, present and future. Biofilm, (2023); 5: 100126.
Heredero-Bermejo I, Gómez-Casanova N, Quintana S, Soliveri J, Javier de la Mata F, Perez-Serrano J et al. In Vitro Activity of Carbosilane Cationic Dendritic Molecules on Prevention and Treatment of Candida Albicans Biofilms. Pharmaceutics, (2020); 12(10): 918.
Sui X, Yan L, Jiang YY. The vaccines and antibodies associated with Als3p for treatment of Candida albicans infections. Vaccine, (2017); 35(43): 5786-5793.
Shukla M, Chandley P, Rohatgi S. The Role of B-Cells and Antibodies against Candida Vaccine Antigens in Invasive Candidiasis. Vaccines, (2021); 9(10): 1159.
Pérez-Laguna V, Barrena-López Y, Gilaberte Y, Rezusta A. In Vitro Effect of Photodynamic Therapy with Different Lights and Combined or Uncombined with Chlorhexidine on Candida spp. Pharmaceutics, (2021); 13(8): 1176.
Guevara-Lora I, Bras G, Juszczak M, Karkowska-Kuleta J, Gorecki A, Manrique-Moreno M et al. Cecropin D-derived synthetic peptides in the fight against Candida albicans cell filamentation and biofilm formation. Frontiers in Microbiology, (2023); 13: 1045984.
Woodburn KW, Clemens LE, Jaynes J, Joubert L-M, Botha A, Nazik H et al. Designed Antimicrobial Peptides for Recurrent Vulvovaginal Candidiasis Treatment. Antimicrobial Agents and Chemotherapy, (2019); 63(11): e02690-18.
Torres R, Barreto-Santamaría A, Arévalo-Pinzón G, Firacative C, Gomez BL, Escandon P et al. In Vitro Antifungal Activity of Three Synthetic Peptides against Candida auris and Other Candida Species of Medical Importance. Antibiotics, (2023); 12(8): 1234.
Gholamine B, Alwaily ER, Fakri Mustafa Y, Habash RT, Naghdi N, et al. An overview of the uses of propolis for oral health. Advancements in Life Sciences, (2023); 10(4): 515-524.
Adeli OA, Prasad KD, Khalaf HA, Hjazi A, Hussien BM, Hussein HA, Naghdi N, Pirhadi M. Phytotherapy in sexual disorder: overview of the most important medicinal plants effective on sexual disorders. Advancements in Life Sciences, (2024); 10(4): 505-14.
García-Tenesaca M, Navarrete ES, Iturralde GA, Villacres Granda IM, Tejera E, Beltran-Ayala P et al. Influence of Botanical Origin and Chemical Composition on the Protective Effect against Oxidative Damage and the Capacity to Reduce In Vitro Bacterial Biofilms of Monofloral Honeys from the Andean Region of Ecuador. International Journal of Molecular Science, (2018); 19(1): 45.
Fernandes L, Ribeiro H, Oliveira A, Silva AS, Freitas A, Henriques M et al. Portuguese honeys as antimicrobial agents against Candida species. Journal of Traditional and Complementary Medicine, (2021); 11(2): 130-136.
de Groot T, Janssen T, Faro D, Cremers NAJ, Chowdhary A, Meis JF. Antifungal Activity of a Medical-Grade Honey Formulation against Candida auris. Journal of Fungi, (2021); 7(1): 50.
Lima WG, Moreira Brito JC, Stephanie da Cruz Nizer W, Sampaio de Assis DC. Antifungal, antibiofilm and anti-resistance activities of Brazilian monofloral honeys against Candida spp. Biocatalysis and Agricultural Biotechnology, (2022); 42: 102335.
Dang QD, Nguyen TTT, Bui CD, Tran-Van H. Antifungal activity against Candida albicans biofilm of Coffea robusta monofloral honey from Vietnam. Notulae Scientia Biologicae, (2024); 16(1): 11600-11600.
Bulgasem BY, Lani MN, Hassan Z, Yusoff WMW, Fnaish SG. Antifungal Activity of Lactic Acid Bacteria Strains Isolated from Natural Honey against Pathogenic Candida Species. Mycobiology, (2016); 44(4): 302-309.
Czernel G, Bloch D, Matwijczuk A, Ciesla J, Kedzierska-Matysek M, Florek M et al. Biodirected Synthesis of Silver Nanoparticles Using Aqueous Honey Solutions and Evaluation of Their Antifungal Activity against Pathogenic Candida Spp. International Journal of Molecular Science, (2021); 22(14): 7715.
Phuna ZX, Yu JKE, Tee JY, Shao QC, Tan NWH, Vijayabalan S et al. In Vitro Evaluation of Nanoemulsions of Curcumin, Piperine, and Tualang Honey as Antifungal Agents for Candida Species. Journal of Applied Biotechnology Reports, (2020); 7(3): 189-197.
Banaeian S, Sereshti M, Rafieian M, Farahbod F, Kheiri S. Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial. Journal of Medical Mycology, (2017); 27(4): 494-500.
Maastricht University Medical Center. A Randomized Controlled Trial: The Effect of a Medical Grade Honey Formulation (L-Mesitran) on Clinical Symptoms of Recurrent Vulvovaginal Candidiasis. clinicaltrials.gov, (2023). Accessed January 1, 2024. https://clinicaltrials.gov/study/NCT05367089
Boahen A, Than LTL, Loke YL, Chew SY. The Antibiofilm Role of Biotics Family in Vaginal Fungal Infections. Frontiers in Microbiology, (2022); 13: 787119.
Di Paola M, Sani C, Clemente AM, Iossa A, Perissi E, Castronovo G et al. Characterization of cervico-vaginal microbiota in women developing persistent high-risk Human Papillomavirus infection. Scientific Reports, (2017); 7(1): 10200.
Chee WJY, Chew SY, Than LTL. Vaginal microbiota and the potential of Lactobacillus derivatives in maintaining vaginal health. Microbial Cell Factories, (2020); 19(1): 203.
Das S, Konwar BK. Prophylactic application of vaginal lactic acid bacteria against urogenital pathogens and its prospective use in sanitary suppositories. International Microbiology, (2024); 27(1): 179-202.
France M, Alizadeh M, Brown S, Ma B, Ravel J. Towards a deeper understanding of the vaginal microbiota. Nature Microbiology, (2022); 7(3): 367-378.
DOI: http://dx.doi.org/10.62940/als.v11i4.3476
Refbacks
- There are currently no refbacks.